Cayman Sams Peptide; Purity- Greater Than Or Equal To 95%; Size-

XL184 is an inhibitor of VEGFR2 (IC₅₀ = 0.035 nM). It is selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4, but also inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC₅₀s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively). XL184 (4.6 nM) inhibits VEGF-induced tubule formation in human microvascular endothelial cells (HMVECs). It reduces migration and invasion of B16/F10 melanoma cells induced by hepatocyte growth factor (HGF) when used at a concentration of 123 nM. XL184 (60 mg/kg) induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model. Unlike sunitinib (Item No. ), XL184 does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model. It also protects primary placental fibroblasts from Zika virus infection. Formulations containing XL184 have been used in the treatment of renal cell and hepatocellular carcinomas.

WARNING This product is not for human or veterinary use.